FINWIRES · TerminalLIVE
FINWIRES

ASX:PME

12 stories mentioning ASX:PMEUpdated 3d ago

Every FINWIRES story that references ASX:PME, newest first.

Asia

Echo IQ Advances US Rollout of AI Platform in June Quarter

Echo IQ (ASX:EIQ) advanced the US rollout of its artificial intelligence-driven EchoSolv platform in the three-month period ended June 30, according to a Monday filing with the Australian bourse.The company secured a binding heads of agreement with Pro Medicus (ASX:PME), establishing the framework for a proposed strategic investment of up to AU$20 million and a commercial reseller partnership across the US, the filing said.The company also secured a data licensing deal with Advara HeartCare, per the filing.Echo IQ shares rose nearly 2% in midday trade Monday, while Pro Medicus shares were down nearly 1%.

ASX:EIQASX:PME
Asia

ASX Biggest Losers

Here are the ASX-listed companies with the biggest losses on Friday.Electro Optic Systems Holdings (ASX:EOS): -6%, AU$8.38Pro Medicus (ASX:PME): -5%, AU$199.56Tamboran Resources (ASX:TBN): -4%, AU$0.23Elevra Lithium (ASX:ELV): -4%, AU$8.67Austal (ASX:ASB): -4%, AU$3.77EVT (ASX:EVT): -3%, AU$12.33Telix Pharmaceuticals (ASX:TLX): -3%, AU$16.36Marimaca Copper (ASX:MC2): -3%, AU$7.51SiteMinder (ASX:SDR): -3%, AU$3.79Codan (ASX:CDA): -3%, AU$43.25

ASX 200ASX:ASBASX:CDAASX:ELVASX:EOSASX:EVTASX:MC2ASX:PMEASX:SDRASX:TBNASX:TLX
Asia

Pro Medicus Growth Not Expected to Be Impeded by Artificial Intelligence, Jefferies Says

Pro Medicus' (ASX:PME) growth is not expected to be impeded by artificial intelligence, but at the current share price, the market seems to be assuming that the firm will have a market share of the US picture archiving and communication system (PACS) market of around 51% by fiscal year 2035, from 11%, according to a Thursday note by Jefferies.The firm's Visage PACS demonstrates class-leading low latency, which continues to drive market share gains. Large data sets, a shift to the cloud, and low growth in radiologists in the US are industry drivers over the medium-term.AI is more likely to enhance Visage's value proposition because of its server-side streaming architecture, enterprise imaging "one viewer" strategy, and its cloud partnerships.The investment firm downgraded Pro Medicus to hold from buy and raised the price target to AU$192.60 per share from AU$147 per share.

ASX:PME
Asia

Australian Shares Retreat; Judo Capital Holdings Cuts Fiscal 2026 Profit Before Tax Guidance

Australian shares declined on Thursday after investors reacted to a continued fall in oil prices as supply concerns eased.The S&P/ASX 200 Index fell 0.68%, or 59.70 points, to close at 8,748.70.Oil prices are reaching pre-war levels as tankers transit through the Strait of Hormuz. Brent crude oil futures fell to around $72 per barrel. Meanwhile, gold fell below $4,000 for the first time since November 2025.On the domestic front, Australia's seasonally adjusted unemployment rate fell to 4.4% in May from 4.5% in April, data from the Australian Bureau of Statistics (ABS) showed.Australia's total household wealth rose 1.2% to AU$19.212 trillion in the March quarter due to growth in land and dwelling values, according to figures released by ABS.Australian total household spending in May was AU$80.64 billion on a current price, seasonally adjusted basis, rising 5.5% year-over-year and 1.3% month-on-month, according to data from the ABS.Seasonally adjusted job vacancies in Australia fell 2.1% to 329,500 in the three months to May, ABS said.In company news, Judo Capital Holdings (ASX:JDO) said it now expects a fiscal 2026 profit before tax of AU$163 million to AU$169 million. The cut comes as Judo now expects its fiscal year cost of risk to be in the range of AU$116 million to AU$122 million, reflecting an increase in certain provisions driven mainly by three exposures across different sectors that recently emerged due to "customer-specific developments." Its shares dropped nearly 38% on close, earlier reaching their lowest point in over two years.Worley (ASX:WOR) increased its expected fiscal 2026 underlying earnings before interest, taxes, and amortization (EBITA) impact to up to AU$60 million, up from a prior estimate of AU$30 million to AU$40 million, due to ongoing Middle East project delays.Lastly, Pro Medicus (ASX:PME) will provide an investment of up to AU$20 million to Echo IQ (ASX:EIQ) and become a reseller of the EchoSolv product suite across the US under a proposed commercial partnership.

ASX 200ASX:EIQASX:JDOASX:PMEASX:WOR
Asia

Pro Medicus to Make Up to AU$20 Million Debt Investment in Echo IQ as Part of Proposed Commercial Partnership

Pro Medicus (ASX:PME) will provide an investment of up to AU$20 million to Echo IQ (ASX:EIQ) and become a reseller of the EchoSolv product suite across the US under a proposed commercial partnership, according to a Thursday filing with the Australian bourse.Subject to definitive documentation, Pro Medicus will initially invest AU$10 million and will have an option to invest an additional AU$10 million upon Echo IQ receiving US Food and Drug Administration clearance for its EchoSolv HF software.Under the agreed framework, both the initial and subsequent investment will be made through a subscription for secured convertible notes, per the filing.The US FDA submission for EchoSolv HF "remains on track for an expected outcome in the near term," Echo IQ said.

ASX:EIQASX:PME
Wire

Market Chatter: Pro Medicus' New Contracts Dispel Fears Over AI Competition, RBC Capital Markets Says

Pro Medicus' (ASX:PME) two recent contract awards in the US will help discredit fears of competitors in the artificial intelligence space eroding long-term demand, RBC Capital Markets said in a note, the Australian Financial Review reported Monday.The company disclosed that US subsidiary Visage Imaging renewed its partnership with Allegheny Health Network through a five-year contract valued at around AU$28 million, and also signed a seven-year contract with TidalHealth valued at AU$16 million.The contracts show that customers remain committed to longer term deals as opposed to shorter agreements that would maintain flexibility for AI-native alternatives, RBC analyst Jackson Lee said, according to the report.The awards also add to traction seen in the company's cloud imaging platform and transaction-based revenue model, RBC reportedly said.The investment firm kept a sector perform rating on Pro Medicus with a share price target of AU$195, AFR reported.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

ASX:PME
Asia

Pro Medicus Signs AU$16 Million Contract With US Healthcare Network TidalHealth

Pro Medicus (ASX:PME) said its Visage Imaging unit in the US signed a seven-year, AU$16 million contract with healthcare network TidalHealth, according to a Monday filing with the Australian bourse.The new contract will be implemented in the cloud and includes Visage Imaging's full stack of software plus the Visage 7 cardiology imaging product.Planning for the rollout will start immediately, with a target to go live in the first quarter of 2027 on a transaction-based model, the company said.

ASX:PME
Asia

Pro Medicus Unit Renews AU$28 Million Deal With Allegheny Health Network

Pro Medicus' (ASX:PME) US subsidiary Visage Imaging has renewed its partnership with Allegheny Health Network (AHN) through a five-year contract valued at around AU$28 million, according to a Monday filing with the Australian bourse.The agreement also broadens AHN's use of Visage technology by incorporating Visage 7 workflow, per the filing.AHN operates an integrated network of 14 hospitals, around 2,500 beds, and over 200 primary and specialty care practices across more than 300 clinical sites, the filing added.

ASX:PME
Asia

Pro Medicus Unit Secures AU$90 Million Deal With Beth Israel Lahey Health; Shares Up 7%

Pro Medicus' (ASX:PME) US subsidiary Visage Imaging signed a seven-year, AU$90 million contract with Beth Israel Lahey Health to deploy its cloud-based Visage 7 platform across the health system, according to a Monday filing with the Australian bourse.The company will also complete the migration from Beth Israel Lahey Health's legacy picture archiving and communication system archives to the Visage 7 open archive and enable enterprise-wide distribution of imaging integrated with the organization's electronic health record, per the filing.The planning for the rollout will start immediately, following Visage's proven cloud-based implementation process, with go-live targeted for the first quarter of 2027, the filing added.The company's shares rose 7% in recent Monday trade.

ASX:PME
Asia

Artrya Appoints CFO

Artrya (ASX:AYA) appointed Clayton Hatch as chief financial officer, effective Sept. 1, according to a Monday filing with the Australian bourse.Hatch most recently served as chief financial officer of Pro Medicus (ASX:PME), per the filing.Richard Jarvis will remain interim CFO during the transition to ensure an orderly handover, the filing added.

ASX:AYAASX:PME
Asia

Pro Medicus Unit Secures AU$37 Million Contract Renewal With Illinois Health System

Pro Medicus' (ASX:PME) Visage Imaging subsidiary signed a five-year contract renewal worth AU$37 million with Northwestern Medicine, an academic health system based in Illinois, according to a Monday filing with the Australian bourse.

ASX:PME
Asia

ASX Preview: Australian Shares Set to Open Lower as US Announces Iran Blockade; Monash IVF Receives Revised Takeover Proposal

Australian shares are set to open lower on Monday after US President Donald Trump said that the US would begin a blockade of the Strait of Hormuz after peace talks between Iran and the US ended without a resolution to the conflict, sending oil prices higher.A report from The Wall Street ​Journal said that Trump and his ​advisers were considering limited ⁠strikes on Iran. Brent crude oil futures soared nearly 8% to a four-week high of $US102.80 per barrel early on Monday. Gold fell almost 2%.In corporate news, Monash IVF Group (ASX:MVF) received a revised, unsolicited, conditional, and non-binding indicative proposal from a consortium comprising Genesis Capital Investment Management and WHSP Holdings (ASX:SOL) to acquire 100% of the shares in Monash IVF via a scheme of arrangement at $0.90 per share.Pro Medicus' (ASX: PME) wholly-owned US unit, Visage Imaging, signed a AU$37 million, five-year contract renewal with Northwestern Medicine.Australia's benchmark index closed just 0.1% lower, or 12.6 points, at 8,960.60 on April 10.

ASX 200ASX:MVFASX:PMEASX:SOL

Track with the FINWIRES app suite

FolioX
FolioX
Track ASX:PME in your portfolio
WheelAI
WheelAI
Analyze ASX:PME options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ASX:PME